Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
SPR720 (Fobrepodacin) | Working Group for New TB Drugs
PPT - SPR720 PowerPoint Presentation, free download - ID:4010237
Spero develops SPR720 for Nontuberculous Mycobacterium | Spero ...
Efficacy of SPR720 in murine models of non-tuberculous mycobacterial ...
SPR720 disodium – Xcess Biosciences
What to learn more about recent Phase 1 data for SPR720 and our plans ...
Spero Therapeutics Announces Publication of SPR720 Phase 1
Spero Therapeutics announces Initiation of SPR720 Phase 1 Clinical Trial
Spero Therapeutics receives ODD for its oral drug SPR720 from the FDA
Spero Therapeutics Provides Update on SPR720 Phase 2a
Full article: Nontuberculous mycobacterial pulmonary disease and the ...
Slide 1
Slide 23
【SPR720】SPR720 CAS号:1384984-31-9【结构式 性质 活性】-化源网
Slide 29
Slide 36
Slide 33
Slide 30
Slide 24
Slide 9
(PDF) First-in-Human Evaluation of the Safety, Tolerability, and ...
Slide 28
Slide 17
Slide 31
Slide 27
Slide 20
Slide 25
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued ...
Slide 19
Slide 38
Slide 35
First-in-Human Evaluation of the Safety, Tolerability, and ...
Infectious Diseases | University of Illinois Chicago
Spero Therapeutics | Developing MDR Bacterial Infection Treatments
Slide 22
Slide 16
Spero Therapeutics: R&D Day on Non-Tuberculous Mycobacteria Pulmonary ...
The drug developers fighting the antibiotic resistance problem ...
Antibiotic Pipeline for Gram-Negative Bacteria | Spero Therapeutics
Slide 32
Intrapulmonary pharmacokinetics of SPR719 following oral administration ...
Slide 15
M. avium Complex Pulmonary Infections: Therapeutic Obstacles and ...
Slide 37
Exploring the 5-Substituted 2-Aminobenzothiazole-Based DNA Gyrase B ...
Slide 40
Slide 26
(PDF) 1637. SPR720, A Novel Benzamidazole Gyrase Inhibitor ...
Slide 4
Slide 34
Slide 39
Pharmacokinetic profile and efficacy of TPP8 in mice. (A) Plasma ...
Spero Therapeutics (SPRO) Stock Price & Overview
Structure-based design, synthesis, computational screening and ...
Spero Therapeutics on LinkedIn: #clinicaltrials
Slide 21
Spero Therapeutics (SPRO) – 2H2019 Readouts | JaguarAnalytics
Slide 6
具有抗结核活性的嘧啶衍生物,European Journal of Medicinal Chemistry - X-MOL
New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum ...
Spero Therapeutics-Aktie: Spannende Nachrichten
Antibacterial Prodrugs to Overcome Bacterial Antimicrobial Resistance
Fobrepodacin | TargetMol
Inhibitors targeting DNA replication and protein synthesis | Download ...
Hydrazineyl-linked imidazole[1,2-a]pyrimidine-thiazole hybrids: design ...
Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable ...
Join a Phase 2a trial for non-tuberculous mycobacterial pulmonary ...
Statistical analysis of food effect on the PK of SPR719 following ...
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and ...
Frontiers | Treatment for non-tuberculous mycobacteria: challenges and ...
Mintz Represents Spero Therapeutics | Mintz
首个口服碳青霉烯类抗生素：GSK 和 Spero达成独家许可协议，共同开发Tebipenem HBr治疗成人复杂性尿路感染 - 知乎
Spero Therapeutics logo in transparent PNG and vectorized SVG formats
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug ...
resmetirom
Fobrepodacin disodium | TargetMol
